Wally Klemp,
CEO of Moleculin, discusses the Company's recent update on the
Phase 2 clinical trial of STAT3 inhibitor in combination with
radiation for the treatment of glioblastoma
Watch the "What This Means" video here
HOUSTON, Sept. 16,
2024 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3
clinical-stage pharmaceutical company with a broad portfolio of
drug candidates targeting hard-to-treat tumors and viruses, today
announced that Walter Klemp,
Chairman and Chief Executive Officer of Moleculin participated in a
Virtual Investor "What this Means" segment.
As part of the segment, Mr. Klemp highlighted the enrollment and
treatment of patients in an investigator-initiated Phase 2 study
evaluating WP1066 in combination with radiation therapy for the
treatment of adults with glioblastoma (NU 21C06). The study is
being conducted under Northwestern
University's Investigative New Drug application (IND) which
cross references the Company's own IND, which received clearance
from the U.S. Food and Drug Administration (FDA) in April 2022. This trial is funded by the National
Institutes of Health (NIH) and BrainUp®, a non-profit organization
dedicated to bringing awareness to brain cancer.
The Virtual Investor "What this Means" segment featuring
Moleculin is now available here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
is a Phase 3 clinical stage pharmaceutical company advancing a
pipeline of therapeutic candidates addressing hard-to-treat tumors
and viruses. The Company's lead program, Annamycin, is a
next-generation anthracycline designed to avoid multidrug
resistance mechanisms and to eliminate the cardiotoxicity common
with currently prescribed anthracyclines. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
The Company is initiating the MIRACLE (Moleculin
R/R AML AnnAraC Clinical Evaluation)
Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating
Annamycin in combination with cytarabine, together referred to as
AnnAraC, for the treatment of relapsed or refractory acute myeloid
leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the
Company believes it has substantially de-risked the development
pathway towards a potential approval for Annamycin for the
treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of viruses, as well as certain cancer indications.
For more information about the Company, please
visit www.moleculin.com and connect on X, LinkedIn and
Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin has attempted to identify
forward-looking statements by terminology including 'believes,'
'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,'
'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,'
'approximately' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These forward-looking statements, include, but are not limited to,
the ability for the study to fill the safety lead-in group of six
subjects on a timely basis and whether the preclinical results will
be demonstrated in the Phase 2 trial . These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission (SEC) and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-participates-in-virtual-investor-what-this-means-segment-302247934.html
SOURCE Moleculin Biotech, Inc.
